To make the best possible comparison, we selected for B-cell lymphomas and Hodgkin lymphomas a tumor-specific antigen (either CD20 or CD30) and assessed the number of PD1-positive T cells that were closer than a defined distance to the center of the tumor cell. This evidence concerns the gene TNFRSF8 and neoplasm.